PolyPid Ltd. (PYPD) Stock

PolyPid Ltd. (PYPD) is a Healthcare stock trading at $4.78 (as of 2026-06-18), with a market capitalization of $85.92M and a trailing P/E of 2.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Valuation — source: SEC EDGAR (first-party)
Price	$4.78
Market Cap	$85.92M
P/E Ratio	2.3
EV / EBITDA	-2.6
Price / Book	7.83
DCF Value (model)	$-25.96
DCF Upside vs Price	-643.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$517000.00
Net Margin	-6609.1%
Return on Equity	-311.4%
Debt / Equity	0.15
Current Ratio	1.97
Revenue Growth (YoY)	17.0%
EPS Growth (YoY)	-57.4%
FCF Growth (YoY)	27.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	-18.77 (distress)

Valuation vs Sector & Industry
Stock P/E	2.3
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-89.2%
vs Industry	-92.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	AIGH Capital Management LLC ($6.98M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Dikla Czaczkes Akselbrad
Employees	57
Country	IL
IPO Date	2020-06-26

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.